Email Alert | RSS    帮助

中国防痨杂志 ›› 2011, Vol. 33 ›› Issue (5): 275-279.

• 论著 • 上一篇    下一篇

利奈唑胺治疗耐多药结核病的初步评价

黄海荣 于霞 姜广路 戴广明 马玙   

  1. 北京市结核病胸部肿瘤研究所,北京,101149
  • 收稿日期:2010-12-02 出版日期:2011-05-20 发布日期:2012-03-15
  • 通信作者: 黄海荣 E-mail:hairong.huangcn@gmail.com
  • 基金资助:

    北京市科技新星计划2007B039

Treatment outcomes of linezolid for multidrug-resistant tuberculosis:a systematic review and meta-analysis

Huang Hairong,Yu Xia,Jiang Guanglu,Dai Guangming,Ma Yu   

  1. Beijing Tuberculosis and Thoracic Tumor Institute; Beijing 101149; China;
  • Received:2010-12-02 Online:2011-05-20 Published:2012-03-15
  • Contact: Huang Hairong E-mail:hairong.huangcn@gmail.com

摘要: 目的  初步评价利奈唑胺治疗耐多药结核(MDR-TB)的有效性与安全性。方法  检索Cochrane图书馆临床对照试验库、Pubmed、Embase、CBM、CNKI、Wanfang Date等电子数据库。对符合纳入标准的临床研究进行统计分析。结果  共有7个国家的5个临床研究符合纳入标准。分析结果表明,含利奈唑胺的联合化疗方案治疗MDR-TB的合并成功率为82%(95%CI 73%~89%);治疗结果为失败、丢失或死亡的比例分别为2%、5%、11%。血液系统不良反应、神经毒性和胃肠道反应的发生率分别为32%、25%、6%。结论  利奈唑胺对耐多药结核病有较好的疗效,但药物不良反应发生率较高。

关键词: 结核, 抗多种药物性/药物疗法, 乙酰胺类, 恶唑烷酮类, 评价研究

Abstract: Objective To evaluate the efficacy and safety of linezolid for treating multidrug resistant tuberculosis(MDR-TB). Methods Cochrane Controlled Trials database, Pubmed, Embase, CBM, CNKI, Wanfang Date and other electronic databases were searched. Clinical studies matched the inclusion criteria would be analysed statistically. Results A total of five clinical studies met the inclusion criteria in seven countries. The Results showed that the mean proportion of patients achieving treatment success was 82% (95% CI 73%—89%); the mean proportion of patients whose outcome were treatment failure,default and death were 2%, 5% and 11%,respectively. The incidence rate of adverse events in hematopoietic system and neurotoxicity and gastrointestinal system were 32%, 25%, 6%, respectively.  Conclusion Linezolid against MDR-TB has a good efficacy, but the incidence of adverse events is higher.

Key words: tuberculosis,multidrug-resistant/drug therapy, acetamides, oxazolidinones, evaluation studies